Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renin-Angiotensin System Clear all
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 4 Interventional

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

NCT00961207
View directory record Official record
Conditions
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria, Albuminuria
Interventions
Aliskiren
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Completed No phase listed Observational Results available

RAAS and Arterial Stiffness in SCI

NCT04510974
View directory record Official record
Conditions
Arterial Stiffness, Renin Angiotensin Aldosterone System, Orthostatic Hypotension, Spinal Cord Injury, Hypotension
Interventions
Spinal Cord Injury
Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 70 Years
Enrollment
33 participants
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Plasma Renin Concentrations in Cardiac Surgery

NCT06895213
View directory record Official record
Conditions
Cardiac Surgery With Cardiopulmonary Bypass
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

NCT01188304
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar, aspirin, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 4:52 AM EDT
Not yet recruiting Phase 4 Interventional

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

NCT06746753
View directory record Official record
Conditions
Septic Shock
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Early Phase 1 Interventional

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

NCT02591173
View directory record Official record
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

NCT00141778
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Placebo, Ramipril, Spironolactone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

NCT00685945
View directory record Official record
Conditions
Obesity
Interventions
Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin, Sildenafil + L-NMMA + bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Withdrawn Not applicable Interventional

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

NCT01009944
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 4 Interventional

QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia

NCT00150826
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Quinapril, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Not yet recruiting Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 28, 2026, 4:52 AM EDT
Terminated Phase 4 Interventional

Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)

NCT01233635
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
no drug, start cozaar, continue cozaar
Other · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 4 Interventional Results available

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

NCT03217591
View directory record Official record
Conditions
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions
IW-1973, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
54
States / cities
Birmingham, Alabama • Chula Vista, California • Fullerton, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2 Interventional

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

NCT00920764
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

NCT00894387
View directory record Official record
Conditions
Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study A

NCT00283686
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional

RAAS Optimization for Acute CHF Patients

NCT03695120
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Change of treatment plan
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 28, 2026, 4:52 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress

NCT02432339
View directory record Official record
Conditions
Psychological Stress, Hypertension, Renal
Interventions
mycophenolate mofetil (MMF), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 28, 2026, 4:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

NCT01324245
View directory record Official record
Conditions
Salt-sensitive Hypertension
Interventions
Fenoldopam
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 28, 2026, 4:52 AM EDT